Apo-A1

Apo-A1 Informations sur la molécule

Nom anglais	Apolipoprotein A-I	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	3	Alias de la cible	Epididymis Secretory Sperm Binding Protein，Apolipoprotein A-I(1-242)，APOA1，ProapoA-I，Apo-AI，Apolipoprotein A1，Apo(A)，ApoA-I，Apolipoprotein A-I，HPALP2
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Apolipoprotein A-I
Alias de la cible	Epididymis Secretory Sperm Binding Protein，Apolipoprotein A-I(1-242)，APOA1，ProapoA-I，Apo-AI，Apolipoprotein A1，Apo(A)，ApoA-I，Apolipoprotein A-I，HPALP2
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	3
Phase de R&D la plus avancée	Phase 2 Clinical

Apo-A1 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
AP1-H5225	Human	HEK293	Human Apo-A1 Protein, His Tag				Ajouter au panier

Quantité totale1

Apo-A1Contexte de la molécule

ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Apo-A1Alias de la molécule

Apolipoprotein A-I,APOA1,MGC117399

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Zerlasiran	SLN-360	Phase 2 Clinical	Silence Therapeutics Plc	Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Hyperlipidemias; Lipid Metabolism Disorders	Details
Fx-5A	Fx-5A	Phase 1 Clinical	Kinemed Inc	Cardiovascular Diseases	Details
Recombinant NV-A01 adenovirus		Phase 1 Clinical	Nanjing Nuowei Biotechnology Co Ltd	Glioblastoma; Solid tumours	Details